Bio-Rad Laboratories (BIO-B) Liabilities and Shareholders Equity (2009 - 2026)

Bio-Rad Laboratories (BIO-B) has 18 years of Liabilities and Shareholders Equity data on file, last reported at $9.8 billion in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $9.8 billion, up 3077.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $40.3 billion (up 316.42% YoY), and the FY2025 annual result was $10.6 billion, up 12.95% from the prior year.
• Liabilities and Shareholders Equity slipped to $9.8 billion in Q1 2026 per BIO-B's latest filing, from $10.6 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $14.4 billion in Q1 2022 and troughed at $300000.0 in Q4 2023.
• A 5-year average of $8.5 billion and a median of $10.2 billion in 2025 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity sank 99.71% in 2022, then surged 3121266.67% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $600000.0 in 2022, then sank by 50.0% to $300000.0 in 2023, then surged by 3121266.67% to $9.4 billion in 2024, then advanced by 12.95% to $10.6 billion in 2025, then declined by 7.44% to $9.8 billion in 2026.
• Business Quant data shows BIO-B's Liabilities and Shareholders Equity at $9.8 billion in Q1 2026, $10.6 billion in Q4 2025, and $9.7 billion in Q3 2025.